Allogene's Autoimmune Data May Already Be Priced Into Expectations

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Allogene reports after the market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual earnings data.

Historical price behavior shows moderate volatility around earnings, with an average absolute Day 0 move of 3.59% and Day +1 move of 6.55%. The Day +1 range averages 12.53%, indicating significant intraday volatility as investors digest the results.

The most recent earnings (August 2026) saw a modest Day 0 decline of 2.36%, followed by a sharper Day +1 drop of 4.35%. This pattern of muted initial reaction followed by larger next-day moves is consistent across several quarters. The May 2026 report showed a small Day 0 gain of 1.30% but a substantial Day +1 decline of 8.15%, while March 2026 saw a 6.08% Day 0 drop followed by a more modest 2.83% Day +1 decline.

Directionally, the stock has moved lower following five of the past eight earnings releases on Day +1, though the magnitude varies considerably. The largest single-day move was a 15.68% decline in May 2025, while November 2025 delivered a positive 12.38% Day +1 gain. Given the upcoming ALLO-329 data presentation just four days after this earnings call, investors may be positioning for that catalyst rather than reacting solely to quarterly financial results, potentially compressing the typical post-earnings volatility window.

Part 2.2: Options Market Expected Move

The options market is pricing a 15.06% expected move by the November 20 expiration, significantly higher than the average historical Day +1 move of 6.55% but in line with the average Day +1 range of 12.53%. This elevated implied volatility likely reflects not just the Q3 earnings on November 5, but also the critical ALLO-329 autoimmune data presentation scheduled for November 9—creating a compressed catalyst window that could drive outsized price action over the two-week period.

Part 3: What Analysts Are Saying

Allogene currently holds a Strong Buy consensus from analysts, with an average recommendation of 4.62 out of 5.0. The breakdown shows 10 Strong Buy ratings, 1 Moderate Buy, and 2 Hold ratings, with no Sell recommendations. This rating structure has remained unchanged over the past month, indicating stable analyst conviction.

The average price target stands at $8.30, representing substantial 597% upside from the current price of $1.19. Price targets range from a low of $2.00 to a high of $14.00, reflecting divergent views on the company's clinical and commercial prospects. The wide target range suggests analysts are weighing both the significant upside potential if key programs succeed and the substantial execution risk inherent in clinical-stage biotechnology.

The unchanged sentiment over the past month indicates analysts are maintaining their bullish stance heading into the dual catalysts of Q3 earnings and the ALLO-329 autoimmune data release. The concentration of Strong Buy ratings—representing 77% of all recommendations—reflects confidence in the company's strategic repositioning and the potential for its off-the-shelf CAR-T platform to address large unmet needs in both oncology and autoimmune disease. However, the current stock price trading at just 14% of the average analyst target suggests the market is pricing in significant probability of clinical or regulatory setbacks.

Part 4: Technical Picture

The Barchart Technical Opinion shows a 100% Sell signal, unchanged from both last week and last month, indicating persistent bearish technical pressure. This strong negative signal has remained consistent despite the company's positive clinical developments.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates significant near-term downward momentum
• Medium-term (100% Sell): Bearish reading suggests continued weakness in the intermediate timeframe
• Long-term (100% Sell): Sell signal reflects sustained deterioration in the longer-term trend

The trend is characterized as Strong and Strengthening, indicating that bearish momentum is not only firmly established but intensifying. This creates a challenging technical backdrop heading into the earnings release and subsequent ALLO-329 data presentation.

The stock is trading at $1.19, positioned above only the 5-day moving average of $1.17 but below all other key moving averages: the 10-day ($1.21), 20-day ($1.28), 50-day ($1.56), 100-day ($1.77), and 200-day ($1.97). This configuration—with the stock below five of six moving averages and all longer-term averages in descending order—forms a classic bearish alignment that technical traders call a "death cross" pattern.

The stock has declined approximately 40% from its 200-day moving average of $1.97, reflecting sustained selling pressure throughout 2026 despite positive clinical milestones. The 50-day moving average at $1.56 represents the nearest significant resistance level, while support appears limited given the stock is trading near its 5-day average.

The technical setup heading into earnings is decidedly bearish, with all momentum indicators pointing lower and the trend strengthening in a negative direction. This creates a high bar for positive surprises—the company would likely need to deliver not just an in-line quarter but also provide compelling forward guidance or clinical updates to reverse the technical deterioration. Conversely, any disappointment could accelerate the downtrend given the lack of nearby technical support. The upcoming ALLO-329 data on November 9 represents a potential catalyst that could override technical factors, but until then, the path of least resistance remains lower.